AlloVir (NASDAQ:ALVR) just reported results for the second quarter of 2024. AlloVir reported earnings per share of -5 cents. This was above the analyst estimate for EPS of -9 cents. The company ...

AlloVir, Inc. (ALVR) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings ...

After Kalaris and AlloVir combine, the new company will have about $100 million to advance a treatment for age-related macular degeneration. Kalaris is a clinical-stage biopharmaceutical company ...

Brett R. Hagen, the Chief Accounting Officer of Allovir, Inc. (NASDAQ:ALVR), a company with a market capitalization of $49.2 million, recently sold a total of $342 worth of the company's common stock.

What is this Case About: AlloVir, Inc. (ALVR) Allegedly Misled Investors Regarding Efficacy of its posoleucel Phase 3 Studies According to the complaint, in March 2022, AlloVir initiated global ...

AlloVir (NASDAQ:ALVR – Get Free Report) is expected to issue its quarterly earnings data before the market opens on Thursday, March 13th.Analysts expect the company to announce earnings of ($2. ...

AlloVir (ALVR) is scheduled to report earnings on March 14, 2025. The last reported earnings were for reported on November 12, 2024 for Q3.

AlloVir (NASDAQ:ALVR) just reported results for the first quarter of 2024. AlloVir reported earnings per share of -26 cents. This was below the analyst estimate for EPS of -18 cents. The company ...